Due to its high bioavailability, after oral administration, WP1066 binds specifically both to JAK2 and JAK2 V617F—the mutated form characteristic for cancer cells, thus inhibiting phosphorylation and kinase activation [63]. The gene discussed is JAK2; the disease is cancer.